FDA Approves Bravnetsa as Bioequivalent and Therapeutically Equivalent Lutetium Lu 177 Dotatate for SSTR-Positive GEP-NETs

Clinical Summary: 

• Regulatory Update: The FDA granted final approval to lutetium Lu 177 dotatate (Bravnetsa; Lantheus) for adults with somatostatin receptor-positive (SSTR-positive) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.
• Approval Pathway: Bravnetsa was approved through the FDA’s Abbreviated New Drug Application pathway and was determined by the FDA to be bioequivalent and therapeutically equivalent to the reference product, lutetium Lu 177 dotatate (Lutathera).
• Clinical Relevance: The approval introduces an additional FDA-approved lutetium Lu 177 dotatate radioligand therapy for adults with SSTR-positive GEP-NETs, potentially expanding treatment availability while maintaining the established therapeutic approach of the reference product.

The US Food and Drug Administration (FDA) has granted final approval to lutetium Lu 177 dotatate (Bravnetsa; Lantheus) for the treatment of adults with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.

Bravnetsa, previously referred to as PNT2003, is a radioligand therapy that is bioequivalent and therapeutically equivalent to lutetium Lu 177 dotatate (Lutathera). The agent was approved through the FDA’s Abbreviated New Drug Application (ANDA) pathway.

According to Lantheus, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to Lutathera and represents the first radioligand therapy approved through the ANDA pathway.

GEP-NETs are neuroendocrine tumors arising within the digestive system and pancreas and may be functional or nonfunctional depending on hormone activity. The prevalence of GEP-NETs in the United States is estimated at approximately 200,000 patients.

Warnings and precautions for Bravnetsa include risks associated with radiation exposure, myelosuppression, secondary myelodysplastic syndrome and leukemia, renal toxicity, hepatotoxicity, hypersensitivity reactions, neuroendocrine hormonal crisis, embryo-fetal toxicity, and infertility.

Because lutetium Lu 177 dotatate contributes to cumulative radiation exposure, radiation safety precautions should be followed during and after treatment. Radioactivity may be detected in the urine for up to 30 days following administration.

Myelosuppression is another important treatment consideration. In NETTER-1, anemia, thrombocytopenia, and neutropenia occurred more frequently with lutetium Lu 177 dotatate plus long-acting octreotide than with high-dose long-acting octreotide. Blood cell counts should be monitored, with treatment interruption, dose reduction, or permanent discontinuation based on severity.

Renal function should also be monitored throughout treatment. Administration of the recommended amino acid solution before, during, and after Bravnetsa is advised to reduce renal radiation exposure, along with appropriate hydration and frequent urination around treatment.

The most common grade 3/4 adverse reactions occurring more frequently with lutetium Lu 177 dotatate included lymphopenia, increased gamma-glutamyl transferase, vomiting, nausea, increased aspartate aminotransferase, increased alanine aminotransferase, hyperglycemia, and hypokalemia.

Long-acting somatostatin analogs should be discontinued at least 4 weeks before each Bravnetsa dose, while short-acting octreotide should be discontinued at least 24 hours before treatment. Repeated administration of high-dose glucocorticoids should also be avoided during therapy.

The approval provides another FDA-approved radioligand therapy option for adults with SSTR-positive GEP-NETs using the established lutetium Lu 177 dotatate treatment approach. Information regarding commercial availability is expected from Lantheus as launch preparations progress.

Source: 

Lantheus. Lantheus receives final FDA approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the only radiopharmaceutical FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA® for the treatment of GEP-NETs. Accessed on: September 23, 2026. https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-receives-final-fda-approval-bravnetsatm-lutetium-lu-177